Virtus Advisers LLC Buys New Shares in Teladoc Health, Inc. $TDOC

Key Points

• Virtus Advisers LLC purchased 43,760 shares of Teladoc Health, Inc. for approximately $348,000 in the first quarter, reflecting growing interest in the stock.
• Multiple institutional investors have increased their stakes in Teladoc, with Golden State Wealth Management LLC and National Bank of Canada FI boosting their holdings significantly during the same period.
• Teladoc's recent quarterly earnings exceeded expectations, reporting a loss per share of ($0.19) against an anticipated ($0.27), with revenue reaching $631.90 million, albeit down 1.6% year-over-year.

Virtus Advisers LLC bought a new stake in Teladoc Health, Inc. (NYSE:TDOC - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 43,760 shares of the health services provider's stock, valued at approximately $348,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Golden State Wealth Management LLC grew its stake in shares of Teladoc Health by 102.6% in the first quarter. Golden State Wealth Management LLC now owns 3,337 shares of the health services provider's stock valued at $27,000 after buying an additional 1,690 shares in the last quarter. National Bank of Canada FI increased its holdings in shares of Teladoc Health by 79.4% during the 1st quarter. National Bank of Canada FI now owns 3,571 shares of the health services provider's stock worth $28,000 after acquiring an additional 1,581 shares during the last quarter. SVB Wealth LLC acquired a new position in shares of Teladoc Health during the 1st quarter worth approximately $37,000. BI Asset Management Fondsmaeglerselskab A S acquired a new position in shares of Teladoc Health during the 1st quarter worth approximately $50,000. Finally, Brucke Financial Inc. acquired a new stake in Teladoc Health during the 4th quarter valued at $92,000. 76.82% of the stock is owned by institutional investors.

Insider Activity at Teladoc Health

In related news, insider Fernando M. Rodrigues sold 4,174 shares of the business's stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $6.91, for a total value of $28,842.34. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Adam C. Vandervoort sold 5,808 shares of the business's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $6.86, for a total value of $39,842.88. Following the completion of the sale, the insider directly owned 69,773 shares of the company's stock, valued at $478,642.78. The trade was a 7.68% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 18,656 shares of company stock valued at $128,189 in the last three months. Corporate insiders own 0.58% of the company's stock.

Analysts Set New Price Targets

TDOC has been the subject of several research reports. Evercore ISI raised their price target on Teladoc Health from $7.00 to $8.00 and gave the company an "in-line" rating in a report on Wednesday, July 9th. Needham & Company LLC reaffirmed a "hold" rating on shares of Teladoc Health in a report on Thursday, May 1st. Stifel Nicolaus cut their price target on Teladoc Health from $9.00 to $8.00 and set a "hold" rating for the company in a report on Thursday, May 1st. Truist Financial cut their price target on Teladoc Health from $10.00 to $9.00 and set a "hold" rating for the company in a report on Tuesday, May 27th. Finally, Canaccord Genuity Group lowered their price objective on Teladoc Health from $14.00 to $12.00 and set a "buy" rating on the stock in a research report on Thursday, May 1st. Six equities research analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the stock. According to data from MarketBeat.com, Teladoc Health currently has a consensus rating of "Hold" and a consensus price target of $9.75.

Teladoc Health Price Performance

Teladoc Health stock opened at $7.6740 on Monday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.58 and a current ratio of 2.67. Teladoc Health, Inc. has a 52 week low of $6.35 and a 52 week high of $15.21. The stock has a market capitalization of $1.36 billion, a P/E ratio of -6.45 and a beta of 1.76. The stock has a fifty day moving average of $7.73 and a 200-day moving average of $8.18.

Teladoc Health (NYSE:TDOC - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The health services provider reported ($0.19) EPS for the quarter, beating analysts' consensus estimates of ($0.27) by $0.08. Teladoc Health had a negative return on equity of 10.13% and a negative net margin of 8.16%.The firm had revenue of $631.90 million for the quarter, compared to analyst estimates of $621.91 million. During the same quarter in the previous year, the company posted ($0.38) EPS. The business's revenue was down 1.6% on a year-over-year basis. Teladoc Health has set its Q3 2025 guidance at -0.350--0.200 EPS. FY 2025 guidance at -1.350--1.000 EPS. On average, sell-side analysts expect that Teladoc Health, Inc. will post -1.16 earnings per share for the current fiscal year.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.

Want to see what other hedge funds are holding TDOC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teladoc Health, Inc. (NYSE:TDOC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.